CSF1R

AcronymDefinition
CSF1RColony Stimulating Factor 1 Receptor
References in periodicals archive ?
About Pacritinib Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.
By means of targeting CSF1R with selective inhibitors we have been able to delay the clinical symptoms of experimental prion disease, also preventing the loss of neurons.
The CSF1R protein is an important receptor in the brain that is primarily present in microglia, a type of immune cells.
Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.
3 045 RASSF1 27 TSG 3q21 [right arrow] q22 049 RBP1, RBP2 22 4q tel 066 4QTEL11 20 Sub Tel 5p tel 068 C84C11/T3 36 Sub Tel 5q33 [right arrow] q35 075 CSF1R 36 7p tel 089 G31341 27 Sub Tel 7p12.
CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored preclinical study showing the potential synergistic effect of combining pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, with an epidermal growth factor receptor (EGFR) inhibitor in decreasing brain tumor initiating cells (BTIC) viability.
for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R for the treatment of patients with myelofibrosis, in the fourth quarter of 2015 and to request accelerated approval for the treatment of patients with intermediate and high-risk myelofibrosis with low platelet counts of less than 50,000 per microliter (< 50,000/uL) for whom there are no approved drugs.
Food and Drug Administration (FDA) following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.
Pacritinib is a unique, kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, which are known targets for many blood cancers and solid tumors," said Mr.
None of the 541 tumors presented mutations in Akt, BRCA2, IDH1, CSF1R, GNAS, Notch1, Smo, STK11, VHL, MLH1, MPL, or MPM1.